Program
Roflumilast
Also written as “Roflumilast Cream 0.15%”, “Roflumilast Cream 0.3%” and “ARQ-151 cream 0.05%”.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Psoriasis · Dermatitis, Atopic · Asthma · Diabetes Mellitus, Type 2, led by 8 companies.
Drug pageRoflumilast: every studyMany companies study it; this page follows only the 61 they lead. All 118 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 340 open or running | phase 4since Mar 30, 2011 | Jun 9, 2003 | none ahead |
| Arcutis Biotherapeutics | 181 open or running | phase 3since Dec 23, 2019 | Dec 29, 2017 | Apr 27, 2028phase 3 · NCT07916480 |
| Huadong Medicineits history only | 31 open or running | phase 3since Sep 30, 2024 | Sep 30, 2024 | Jun 30, 2027phase 3 · NCT07683806 |
| FLUIDDA nvits history only | 20 open or running | phase 4since Nov 21, 2011 | Nov 21, 2011 | none ahead |
| Integrative Skin Science and Researchits history only | 11 open or running | phase 4since Apr 23, 2026 | Apr 23, 2026 | Aug 2027phase 4 · NCT07560618 |
| Padagisits history only | 10 open or running | phase 3since Feb 28, 2023 | Feb 28, 2023 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 2since Jan 25, 2016 | Jan 25, 2016 | none ahead |
| Takedaits history only | 10 open or running | phase 1since Mar 4, 2014 | Mar 4, 2014 | none ahead |
Also a collaborator on its studies: Tanabe Pharma, Fougera Pharmaceuticals and Pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Arcutis Biotherapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Dec 29, 2017.
- Nov 30, 2018Phase 2 study in Plaque PsoriasisNCT03764475 · 332 enrolled · United States, Canada
- Apr 10, 2019Phase 2 study in Dermatitis, AtopicNCT03916081 · 136 enrolled · United States, Canada
- Nov 3, 2019Phase 1 study in Dermatitis, AtopicNCT04156191 · 101 enrolled · United States
- Dec 23, 20192 phase 3 studies in Chronic Plaque PsoriasisNCT04211389, NCT04211363
- Jan 15, 2020Phase 1 study in Plaque PsoriasisNCT04279119 · 26 enrolled · United States
- Feb 25, 2020Phase 3 study in Chronic Plaque PsoriasisNCT04286607 · 337 enrolled · United States, Canada, Dominican Republic
- Nov 30, 2020Phase 2 study in PsoriasisNCT04655313 · 20 enrolled · United States, Canada, Dominican Republic
- Feb 5, 2021Phase 2 study in PsoriasisNCT04746911 · 10 enrolled · United States, Canada, Dominican Republic
- Feb 24, 20212 phase 3 studies in Atopic Dermatitis EczemaNCT04773600, NCT04773587
- Mar 16, 2021Phase 3 study in Atopic Dermatitis EczemaNCT04804605 · 1,220 enrolled · United States, Canada
- Apr 11, 2021Phase 3 study in Atopic Dermatitis EczemaNCT04845620 · 652 enrolled · United States, Canada
- Aug 25, 2021Phase 3 study in Scalp PsoriasisNCT05028582 · 432 enrolled · United States, Canada
- May 5, 2025Phase 2 study in Dermatitis, AtopicNCT06998056 · 101 enrolled · United States, Canada, Dominican Republic
- Oct 30, 2026Phase 3 study in Dermatitis, AtopicNCT07916480 · 415 planned · United States
Ahead
- Apr 27, 2028Primary completion: phase 3 study in Dermatitis, AtopicNCT07916480
TargetBeta
“An orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities”NCIt, by rule
“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule
Other programs on the same 5 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ensifentrinerule | Merck | phase 3 | 17 |
Studies
All 18 Arcutis Biotherapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07916480Dermatitis, Atopic · United States | 3 | Recruiting | Apr 27, 2028 | 415 |
| NCT06998056Dermatitis, Atopic · United States, Canada, Dominican Republic | 2 | Completed | Dec 4, 2025 | 101 |
| NCT05028582Scalp Psoriasis · United States, Canada | 3 | Completed | Jun 3, 2022 | 432 |
| NCT04845620Atopic Dermatitis Eczema · United States, Canada | 3 | Completed | Jun 1, 2023 | 652 |
| NCT04804605Atopic Dermatitis Eczema · United States, Canada | 3 | Completed | May 28, 2024 | 1,220 |
| NCT04773600Atopic Dermatitis Eczema · United States, Canada | 3 | Completed | Sep 29, 2022 | 683 |
| NCT04773587Atopic Dermatitis Eczema · United States, Canada | 3 | Completed | Aug 30, 2022 | 654 |
| NCT04746911Psoriasis · United States, Canada, Dominican Republic | 2 | Completed | May 11, 2022 | 10 |
| NCT04655313Psoriasis · United States, Canada, Dominican Republic | 2 | Completed | Jan 12, 2022 | 20 |
| NCT04286607Chronic Plaque Psoriasis · United States, Canada, Dominican Republic | 3 | Completed | Jan 22, 2024 | 337 |
| NCT04279119Plaque Psoriasis · United States | 1 | Completed | Mar 25, 2021 | 26 |
| NCT04211389Chronic Plaque Psoriasis · United States, Canada | 3 | Completed | Nov 23, 2020 | 442 |
| NCT04211363Chronic Plaque Psoriasis · United States, Canada | 3 | Completed | Nov 16, 2020 | 439 |
| NCT04156191Dermatitis, Atopic · United States | 1 | Completed | May 2, 2023 | 101 |
| NCT03916081Dermatitis, Atopic · United States, Canada | 2 | Completed | Nov 4, 2019 | 136 |
| NCT03764475Plaque Psoriasis · United States, Canada | 2 | Completed | Oct 8, 2020 | 332 |
| NCT03638258Plaque Psoriasis · United States, Canada | 2 | Completed | May 29, 2019 | 331 |
| NCT03392168Psoriasis · United States, Canada | 2 | Completed | May 2, 2018 | 91 |
How it is read
Names in the registry
- “Roflumilast”, 37 entries
- “Roflumilast Cream 0.15%”, 5 entries
- “Roflumilast Cream 0.3%”, 3 entries
- “ARQ-151 cream 0.05%”, 2 entries
- “Roflumilast Foam 0.3%”, 2 entries
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 21 studies
- Psoriasis, 13 studies
- Dermatitis, Atopic, 11 studies
- Asthma, 8 studies
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.